Caroline Moughon
Family · Columbia, MDNPI 1447746144
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,861 of the $25,319 with a category attached, or 66.6%. 25 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 48.4% of the total. Reporting peaked in 2023 at $13,479 and has fallen 93.6% since, to $865 in 2025. Among family clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $156.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$12K
- Sanofi$11K
- AstraZeneca$561
- GSK$358
- Genentech USA, Inc.$269
- Optinose US, Inc.$223
- plus $992 from 19 others
What the payments were for
- Consulting fees$7633%
- Speaking & faculty fees$16,86167%
- Travel & lodging$3,01312%
- Food & beverage$4,56818%
- Education$1140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 33 | $12,251 |
| Sanofi | 43 | $10,667 |
| AstraZeneca(2 entities) | 21 | $561 |
| GSK | 15 | $358 |
| Genentech USA, Inc. | 3 | $269 |
| Optinose US, Inc. | 12 | $223 |
| Novartis | 5 | $120 |
| Vertos Medical, Inc. | 1 | $117 |
| Sanofi-aventis U.S. LLC | 2 | $114 |
| AbbVie | 5 | $111 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $103 |
| Jazz Pharmaceuticals Inc. | 1 | $83 |
| Pfizer | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $53 |
| Boehringer Ingelheim | 2 | $34 |
| Organon | 1 | $25 |
| Lilly USA, LLC | 1 | $24 |
| Grifols USA, LLC | 1 | $24 |
| Incyte Corporation | 1 | $22 |
| Amgen | 1 | $21 |
| Galderma Laboratories, L.p. | 1 | $21 |
| Biocryst US Sales Co., LLC | 1 | $18 |
| Ionis Pharmaceuticals, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$21,796
- XOLAIR$247
- mild Device Kit$117
- Strensiq$112
- TEZSPIRE$110
How this compares
$25,319 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 26 | $984 |
| Montelukast Sodium | 35 | $769 |
| Levocetirizine Dihydrochloride | 17 | $682 |
| Ipratropium Bromide | 22 | $614 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $365 |
| Fluticasone Propionate | 15 | $192 |
| Famotidine | 13 | $23 |
| Prednisone | 11 | $10 |
Paid to pharmacies, not to this prescriber.
Other family in Columbia
- Grace FitzpatrickColumbia$12K
- Tricia CarvalhoColumbia$9K
- Hannah ClevengerColumbia$9K
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Ariana ChaoLutherville$85K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.